Spero Therapeutics, Inc.
SPRO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.03 | 0.02 | 0.32 |
| FCF Yield | -42.12% | -42.59% | -11.89% | -13.00% |
| EV / EBITDA | -0.10 | 0.25 | 0.87 | -4.47 |
| Quality | ||||
| ROIC | -116.05% | 12.97% | -40.25% | -57.21% |
| Gross Margin | -101.67% | 50.43% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.34 | -1.45 | 0.17 | 0.72 |
| Growth | ||||
| Revenue 3-Year CAGR | -0.41% | 223.34% | 73.32% | -44.69% |
| Free Cash Flow Growth | 28.95% | -326.79% | 87.98% | 25.25% |
| Safety | ||||
| Net Debt / EBITDA | 0.67 | -2.61 | 2.39 | 1.21 |
| Interest Coverage | 0.00 | 0.00 | -16.20 | -45.35 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 371.67 | 168.52 | 8.14 | 314.00 |